Verastem Names New CEO as It Prepares Cancer Drug for Late-Stage Trials
Verastem CEO Daniel Paterson will retire after three years as the company prepares to advance its oral cancer therapy into late-stage trials.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.